Risankizumab, guselkumab, and ustekinumab were associated with the lowest risk for progression from psoriasis to psoriatic arthritis.
Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International stock ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results